Internal Medicine, Rheumatology · Los Angeles, CA
NPI
1326080060
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1245 Wilshire Blvd Ste 775
Los Angeles, CA, 90017
Phone (213) 484-5397
Groups this clinician bills Medicare through
Medicare paid, 2024
$389K
20,124 services
Medicare patients, 2024
348
Average age 74
Drug cost, 2024
$2.8M
6,160 prescriptions
Company payments, 2025
$7,148
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Wagdy W Kades was code J1010 (injection, methylprednisolone acetate, 1 mg), 1,720 times for 46 patients. In total Wagdy W Kades billed 20,124 services in 31 codes, and Medicare paid $389K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-09-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,720 | 46 | $0.10 | $170 |
| 99214 Office E&M - Established | Office | 811 | 325 | $108.29 | $88K |
| 20611 Joint Injection | Office | 184 | 73 | $88.84 | $16K |
| 99211 Office E&M - Established | Office | 151 | 69 | $20.84 | $3,146 |
| J7321 Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | Office | 124 | 34 | $55.91 | $6,933 |
| 96365 Intravenous Infusion, Hydration | Office | 64 | 13 | $57.92 | $3,707 |
| 99204 Office E&M - New | Office | 50 | 50 | $141.83 | $7,092 |
| 99213 Office E&M - Established | Office | 34 | 31 | $82.37 | $2,801 |
| 99215 Office E&M - Established | Office | 29 | 27 | $161.61 | $4,687 |
| J1030 Injection, methylprednisolone acetate, 40 mg | Office | 26 | 26 | $3.88 | $101 |
| 76942 Ultrasound - Nonspecific | Office | 21 | 17 | $55.03 | $1,156 |
| 20550 Musculoskeletal | Office | 17 | 14 | $53.01 | $901 |
By year: 2022 $485K for 20,903 services; 2023 $412K for 22,644 services; 2024 $389K for 20,124 services.
Medicare prescription drug claims, 2024
In 2024, the drug Wagdy W Kades prescribed most often to Medicare patients was Gabapentin, with 615 prescriptions and refills. In total Wagdy W Kades wrote 6,160 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 615 | 683 | 168 | $3,943 |
| Methotrexate Methotrexate Sodium | 571 | 714 | 101 | $6,398 |
| Diclofenac Sodium Generic | 477 | 499 | 186 | $22K |
| Hydroxychloroquine Sulfate Generic | 390 | 484 | 70 | $10K |
| Celecoxib Generic | 361 | 402 | 87 | $6,853 |
| Alendronate Sodium Generic | 346 | 687 | 96 | $2,073 |
| Pregabalin Generic | 311 | 317 | 88 | $8,866 |
| Baclofen Generic | 307 | 392 | 103 | $5,012 |
| Duloxetine Hcl Generic | 252 | 322 | 75 | $5,448 |
| Prolia Denosumab | 211 | 1,255 | 135 | $331K |
| Prednisone Generic | 201 | 206 | 50 | $1,167 |
| Meloxicam Generic | 165 | 175 | 39 | $281 |
| Allopurinol Generic | 151 | 252 | 38 | $993 |
| Tramadol Hcl Generic | 140 | 140 | 35 | $571 |
| Mycophenolate Mofetil Generic | 122 | 185 | 25 | $13K |
Brand drugs: 737 claims; generic drugs: 5,423 claims; opioid claims: 183.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Wagdy W Kades $7,148 ($7,148 in general payments such as food, travel and fees) from 23 companies. The largest payer was Janssen Biotech, Inc. with $2,899.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 17 | $2,899 |
| Amgen Inc. AMGN | 48 | $1,065 |
| Abbvie Inc. ABBV | 30 | $629 |
| ANI Pharmaceuticals, Inc. ANIP | 19 | $360 |
| Pfizer Inc. PFE | 11 | $309 |
| UCB, Inc. UCB.BR | 13 | $299 |
| GlaxoSmithKline, LLC. GSK | 13 | $297 |
| Mallinckrodt Hospital Products Inc. | 17 | $289 |
| Lilly USA, LLC LLY | 8 | $198 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $157 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.